Roivant Sciences Share Price Today
(NASDAQ: ROIV)

Name: Roivant Sciences Share Price Today (NASDAQ: ROIV) - Roivant Sciences Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Roivant Sciences share price is $11.13 & ₹964.30 as on 1 Feb 2025, 2.30 'hrs' IST

$11.13

▲

-0.24

(-2.11%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Roivant Sciences share price in Dollar and Rupees. Guide to invest in Roivant Sciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Roivant Sciences, along with analyst recommendations, forecasts, and comprehensive financials.

Roivant Sciences share price movements

Today's Low: $11.12
Today's High: $11.48
$11.13
0.09%
Downside
Day's Volatility :3.14%
Upside
3.05%
52 Weeks Low: $9.69
52 Weeks High: $13.06
$11.13
12.94%
Downside
52 Weeks Volatility :25.78%
Upside
14.75%

Roivant Sciences (ROIV) Returns

Period	Roivant Sciences Ltd.	Sector (Health Care)	Index (Russel 2000)
3 Months	-3.47%	-0.6%	0.0%
6 Months	8.06%	-2.8%	0.0%
1 Year	11.08%	3.3%	0.0%
3 Years	58.32%	11.6%	-13.7%

Roivant Sciences (ROIV) Key Statistics

in dollars & INR

Previous Close	$11.37
Open	$11.41
Today's High	$11.48
Today's Low	$11.12
Market Capitalization	$8.3B
Today's Volume	$3.6M
52 Week High	$13.055
52 Week Low	$9.69
Revenue TTM	$129.1M
EBITDA	$-1.2B
Earnings Per Share (EPS)	$5.54
PE Ratio	2.05
Profit Margin	3725.1%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	128.96%

How to invest in Roivant Sciences Stock (ROIV) from India?

It is very easy for Indian residents to invest directly in Roivant Sciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Roivant Sciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Roivant Sciences or ROIV on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Roivant Sciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Roivant Sciences shares which would translate to 0.078 fractional shares of Roivant Sciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Roivant Sciences, in just a few clicks!

Returns in Roivant Sciences (ROIV) for Indian investors in Rupees

The Roivant Sciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Roivant Sciences investment value today

Current value as on today

₹1,15,637

Returns

₹15,637

(+15.64%)

Returns from Roivant Sciences Stock

₹11,078 (+11.08%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Roivant Sciences (ROIV)

-5%

Period: Jan 2, 2025 to Feb 1, 2025. Change in 30 Days versus previous period

Search interest for Roivant Sciences Stock from India on INDmoney has decreased by -5% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Roivant Sciences

SB INVESTMENT ADVISERS (UK) LTD
9.06%
Qvt Financial LP
9.04%
Viking Global Investors LP
7.43%
FMR Inc
6.75%
BlackRock Inc
5.76%
Vanguard Group Inc
5.73%

Analyst Recommendation on Roivant Sciences

Buy

88%Buy

11%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Roivant Sciences(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Roivant Sciences Stock (ROIV)

What analysts predicted

Upside of 45.04%

Target:

$16.14

Current:

$11.13

Insights on Roivant Sciences Stock (Ticker Symbol: ROIV)

Price Movement
In the last 3 years, ROIV stock has moved up by 55.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 55.13M → 4.47M (in $), with an average decrease of 91.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 95.29M → -230.18M (in $), with an average decrease of 341.5% per quarter
ROIV vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 55.1% return, outperforming this stock by 44.4%
ROIV vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 87.2% return, outperforming this stock by 31.8%
Price to Sales
ForROIV every $1 of sales, investors are willing to pay $66.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.4 for every $1 of sales.

ROIV Roivant Sciences Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$2.3M	-
Net Income	$-1.0B	-
Net Profit Margin	-44.8K%	-

	FY20	Y/Y Change
Revenue	$67.7M	↑ 2812.61%
Net Income	$1.2B	↓ 215.22%
Net Profit Margin	1.8K%	↑ 46608.72%

	FY21	Y/Y Change
Revenue	$23.8M	↓ 64.85%
Net Income	$-809.2M	↓ 167.41%
Net Profit Margin	-3.4K%	↓ 5174.43%

	FY22	Y/Y Change
Revenue	$55.3M	↑ 132.34%
Net Income	$-845.3M	↑ 4.45%
Net Profit Margin	-1.5K%	↑ 1871.97%

	FY23	Y/Y Change
Revenue	$61.3M	↑ 10.84%
Net Income	$-1.0B	↑ 19.37%
Net Profit Margin	-1.6K%	↓ 117.7%

	FY24	Y/Y Change
Revenue	$124.8M	↑ 103.65%
Net Income	$4.3B	↓ 531.0%
Net Profit Margin	3.5K%	↑ 5131.45%

	Q2 FY23	Q/Q Change
Revenue	$21.6M	↓ 21.01%
Net Income	$-291.8M	↑ 66.35%
Net Profit Margin	-1.3K%	↓ 708.71%

	Q3 FY23	Q/Q Change
Revenue	$37.1M	↑ 71.57%
Net Income	$-304.3M	↑ 4.29%
Net Profit Margin	-820.27%	↑ 529.23%

	Q4 FY23	Q/Q Change
Revenue	$37.1M	↑ 0.11%
Net Income	$5.1B	↓ 1774.58%
Net Profit Margin	13.7K%	↑ 14541.82%

	Q1 FY24	Q/Q Change
Revenue	$28.9M	↓ 22.11%
Net Income	$-151.1M	↓ 102.97%
Net Profit Margin	-522.35%	↓ 14243.9%

	Q2 FY24	Q/Q Change
Revenue	$55.1M	↑ 90.57%
Net Income	$95.3M	↓ 163.06%
Net Profit Margin	172.85%	↑ 695.2%

	Q3 FY24	Q/Q Change
Revenue	$4.5M	↓ 91.88%
Net Income	$-230.2M	↓ 341.54%
Net Profit Margin	-5.1K%	↓ 5316.63%

	FY19	Y/Y Change
Profit	$1.7M	-

	FY20	Y/Y Change
Profit	$66.6M	↑ 3774.16%

	FY21	Y/Y Change
Profit	$21.7M	↓ 67.34%

	FY22	Y/Y Change
Profit	$46.3M	↑ 113.08%

	FY23	Y/Y Change
Profit	$48.2M	↑ 3.96%

	FY24	Y/Y Change
Profit	$96.8M	↑ 101.09%

	Q2 FY23	Q/Q Change
Profit	$17.4M	↓ 24.96%

	Q3 FY23	Q/Q Change
Profit	$33.8M	↑ 94.34%

	Q4 FY23	Q/Q Change
Profit	$33.5M	↓ 1.07%

	Q1 FY24	Q/Q Change
Profit	$24.5M	↓ 26.75%

	Q2 FY24	Q/Q Change
Profit	$51.2M	↑ 108.64%

	Q3 FY24	Q/Q Change
Profit	$2.4M	↓ 95.26%

	FY19	Y/Y Change
Operating Cash Flow	$-1.0B	-
Investing Cash Flow	$-57.6M	-
Financing Cash Flow	$767.0M	-

	FY20	Y/Y Change
Operating Cash Flow	$-761.8M	↓ 25.62%
Investing Cash Flow	$1.7B	↓ 3041.94%
Financing Cash Flow	$217.2M	↓ 71.69%

	FY21	Y/Y Change
Operating Cash Flow	$-552.1M	↓ 27.52%
Investing Cash Flow	$-31.7M	↓ 101.87%
Financing Cash Flow	$456.3M	↑ 110.1%

	FY22	Y/Y Change
Operating Cash Flow	$-677.7M	↑ 22.75%
Investing Cash Flow	$303.3M	↓ 1056.71%
Financing Cash Flow	$306.8M	↓ 32.76%

	FY23	Y/Y Change
Operating Cash Flow	$-843.4M	↑ 24.44%
Investing Cash Flow	$-44.3M	↓ 114.6%
Financing Cash Flow	$499.5M	↑ 62.8%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-249.9M	↑ 39.56%
Investing Cash Flow	$105.0K	↓ 99.91%
Financing Cash Flow	$7.5M	↓ 96.45%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-196.4M	↓ 21.41%
Investing Cash Flow	$-36.5M	↓ 34815.24%
Financing Cash Flow	$207.9M	↑ 2680.15%

Roivant Sciences Technicals Summary

Sell

Neutral

Buy

Roivant Sciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Roivant Sciences (ROIV) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Roivant Sciences Ltd.	-7.86%	8.06%	11.08%	58.32%	19.04%
Biontech Se	7.35%	57.95%	32.59%	-29.28%	275.97%
Regeneron Pharmaceuticals, Inc.	-5.9%	-37.18%	-28.13%	8.42%	89.04%
Vertex Pharmaceuticals Incorporated	13.78%	-3.19%	7.65%	89.41%	92.64%
Alnylam Pharmaceuticals, Inc.	16.13%	2.38%	58.94%	90.38%	126.17%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Roivant Sciences Ltd.	2.05	2.05	NA	-0.73	1.29	-0.18	NA	7.03
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.89	16.89	1.06	44.96	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.15	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Roivant Sciences Ltd.	Buy	$8.3B	19.04%	2.05	3725.1%
Biontech Se	Buy	$29.0B	275.97%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.1B	89.04%	16.89	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$112.9B	92.64%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.7B	126.17%	NA	-15.86%

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Organization	Roivant Sciences
Employees	908
CEO	Mr. Matthew Gline
Industry	Financial

Management People of Roivant Sciences

Name	Title
Mr. Matthew Gline	CEO & Director
Dr. Mayukh Sukhatme M.D.	President, Chief Investment Officer & Director
Mr. Richard Pulik	Chief Financial Officer
Ms. Rakhi Kumar	Chief Accounting Officer
Dr. Eric Venker M.D., Pharm.D.	President & COO
Mr. Drew Kramer	Chief Information Officer
Mr. Josh Chen J.D.	General Counsel
Ms. Kelly Graff	Head of People
Mr. Alex Gasner	Executive Vice President of Roivant Health
Dr. Matt Maisak	Chief Operating Officer of Roivant Platforms

Important FAQs about investing in ROIV Stock from India :

What is Roivant Sciences share price today?

Roivant Sciences share price today stands at $11.13, Open: $11.41 ; Previous Close: $11.37 ; High: $11.48 ; Low: $11.12 ; 52 Week High: $13.06 ; 52 Week Low: $9.69.

The stock opens at $11.41, after a previous close of $11.37. The stock reached a daily high of $11.48 and a low of $11.12, with a 52-week high of $13.06 and a 52-week low of $9.69.

Can Indians buy Roivant Sciences shares?

Yes, Indians can invest in the Roivant Sciences (ROIV) from India.

With INDmoney, you can buy Roivant Sciences at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Roivant Sciences at zero transaction cost.

How can I buy Roivant Sciences shares from India?

It is very easy to buy Roivant Sciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Roivant Sciences (ROIV) be purchased?

Yes, you can buy fractional shares of Roivant Sciences with INDmoney app.

What are the documents required to start investing in Roivant Sciences stocks?

To start investing in Roivant Sciences, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.